​Head & Neck

• (101-21) A Phase 1 Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors

• (108-19) ROMAN: A Study to Investigate the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer (Phase 3 clinical trial, appropriate for patients with oral mucositis.)

• (134-17) Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 (Phase 2 clinical trial, appropriate for patients with lung, head or neck cancer.)

• (144-17) Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery (Phase 2 clinical trial, appropriate for patients with head and neck cancer.)

• (155-17) 0C 17-1: Phase 1 Multi-center Study of the Safety Pharmacokinetics and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors and C-Met Dysregulation (Phase 1 clinical trial, appropriate for patients with advanced solid malignancies.)

• (157-17) FID-007 in Treating Participants With Advanced Solid Tumors (Phase 1 clinical, appropriate for patients with advanced solid malignancies.)

• (161-19) PET MRI as a Staging Tool for Head and Neck Cancer (Clinical research study, appropriate for patients with head and neck cancer.)

• (178-18) A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
• (187-17) Trial of ZW25 in Patients With Advanced HER2-expressing Cancers(Phase 1 clinical trial, appropriate for patients with HER2-expressing cancers.)

• (187-19) A Phase 1/2 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer (Phase 1 clinical trial, appropriate for patients with advanced solid tumors.)

• (189-18) ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors (Phase 2 clinical trial, appropriate for patients with metastatic solid tumors.)

• (201-19) A Phase 1 Study of AGEN1223, a Bispecific Fc-Engineered Anti-GITR-OX40 Antibody in Subjects with Advanced Solid Tumors (Phase 1 clinical trial, appropriate for patients with advanced solid tumors.)

• (205-19) Study to Assess AFM24 in Advanced Solid Cancers (Phase 1/2a clinical trial, appropriate for patients with advanced solid tumors.)

• (214-17) An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread (Phase 1/2 clinical trial, appropriate for patients with advanced malignant tumors.)

Certain clinical trials may not be listed on ClinicalTrials.gov. To learn more about these or other clinical trials, please call 949-764-5543 or contact us online.